

# Libya

## Tuberculosis profile

Population 2015

6.3 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.68 (0.4–1)	11 (6.3–16)
Mortality (HIV+TB only)	0.022 (0.012–0.035)	0.35 (0.19–0.56)
Incidence (includes HIV+TB)	2.5 (1.6–3.6)	40 (26–57)
Incidence (HIV+TB only)	0.055 (0.034–0.079)	0.87 (0.55–1.3)
Incidence (MDR/RR-TB)**	0.12 (0.069–0.16)	1.9 (1.1–2.5)

Estimated TB incidence by age and sex (thousands)\*, 2015

	0-14 years	> 14 years	Total
Females	0.13 (0.059–0.21)	0.89 (0.4–1.4)	1 (0.46–1.6)
Males	0.12 (0.07–0.17)	1.4 (0.94–1.8)	1.5 (1–2)
Total	0.25 (0.16–0.35)	2.3 (1.7–2.8)	2.5 (1.6–3.6)

TB case notifications, 2015

Total cases notified	1 014
Total new and relapse	966
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	100%
- % pulmonary	63%
- % bacteriologically confirmed among pulmonary	76%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	39% (27–60)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.29 (0.15–0.51)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	21	2%
- on antiretroviral therapy		

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			33 (26–39)
Estimated % of TB cases with MDR/RR-TB	3.9% (2.9–5)	16% (12–19)	
% notified tested for rifampicin resistance			
MDR/RR-TB cases tested for resistance to second-line drugs			
Laboratory-confirmed cases		MDR/RR-TB: , XDR-TB:	
Patients started on treatment ****		MDR/RR-TB: 0, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	57%	1 153
Previously treated cases, excluding relapse, registered in 2014	48%	33
HIV-positive TB cases, all types, registered in 2014	26%	54
MDR/RR-TB cases started on second-line treatment in 2013		
XDR-TB cases started on second-line treatment in 2013		

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2016

National TB budget (US\$ millions)


\* Ranges represent uncertainty intervals

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history


\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)



Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




Incidence


Notified (new and relapse)

Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



New and relapse


Retreatment, excluding relapse

HIV-positive

MDR/RR-TB

XDR-TB

Total budget (US\$ millions)



Unfunded

Funded internationally

Funded domestically